Focused on regulation and innovation in the Automotive Industry, this conference offers a unique and robust examination of disruptive forces molding the modern automotive technology.
Keynote Speaker:
- Carla Bailo, President & CEO – Center for Automotive Research
Panel Discussions:
Brave New World: Emerging Legal Issues in the Automotive Sector
- Moderator: Steve Hilfinger, Partner – Foley & Lardner LLP
- Panelist: Pavan Agarwal, Partner – Foley & Lardner LLP
- Panelist: Ellen Clark, Managing Director – Greenwich Capital Group
- Panelist: Kimberly Chainey, Associate General Counsel – Avis Budget Group
- Panelist: Christopher Swift, Partner – Foley & Lardner LLP
Proceed with Caution: Examining Legal Scrutiny of Autonomous Vehicles
- Moderator: Neal Walters, Partner & Practice Leader, Product Liability and Mass Tort Group – Ballard Spahr
- Panelist: Thomas Branigan, Managing Partner – Bowman & Brooke LLP
- Panelist: Bryan Casey, Legal Fellow – Center for Automotive Research at Stanford
- Panelist: Nandi Chhabra, Legal Counsel & Market Development – Peloton Technology
- Panelist: Chris Grigorian, Partner – Foley & Lardner LLP
Who Should Attend:
- Corporate Counsel
- Law Firm Attorneys
- Risk and Compliance Professionals
- Automotive Industry Executives & Senior Leaders
Click here to register and view the full agenda. Foley guest registrations are complimentary. Simply enter code AUTO100 during online registration to reserve your seat.
People
Related Insights
June 3, 2025
Foley Corporate Governance Update
Texas Senate Bill 2337: Protecting Texas Companies and Their Directors, Shareholders and Boards from Proxy Advice Not in the Financial Interests of Shareholders
On June 2, 2025, the Texas Legislature passed Senate Bill 2337, meaningfully regulating proxy advisors like ISS and Glass Lewis when providing proxy voting recommendations concerning Texas companies.
September 25, 2025
Events
Unclaimed Property Roundtable with Delaware State Escheator and Leading Practitioners
June 3, 2025
Health Care Law Today
GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health
Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity.